MentionFox
Home › Executive changes › Charles River Laboratories International, Inc.
Leadership changes · CRL · SEC Form 8-K, Item 5.02

Leadership changes at Charles River Laboratories International, Inc. (2026)

Before you join, sell to or invest in Charles River Laboratories International, Inc.

MentionFox check on Charles River Laboratories International, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/charles-river-laboratories-international

Check Charles River Laboratories International, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Charles River Laboratories International, Inc.?

Who joined and who left Charles River Laboratories International, Inc. (CRL)? 1 appointment reported from 2026-01-09 to 2026-02-18, each cited to the company's own filing.

James C. Foster was named Chief Executive Officer of Charles River Laboratories International, Inc., effective May 5, 2026. As of November 14, 2026, Charles River Laboratories International, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 9, 2026 to February 18, 2026, naming 1 appointment (Form 8-K, January 9, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

NOMURA HOLDINGS INC also filed stake reports on 21 other companies ↓

Sell to companies like Charles River Laboratories International, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)1
Latest filing2026-02-18

Charles River Laboratories International, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-09 to 2026-02-18. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Charles River Laboratories International, Inc. files it.

Also on the record for Charles River Laboratories International, Inc.

DateRecordFigureOur pageSource
November 10, 2026Stake report, Schedule 13G/A, by Invesco Ltd.3.9% of the class5%+ stakesSource
November 5, 2026Stake report, Schedule 13G/A, by FMR LLC12.4% of the class5%+ stakesSource
September 8, 2026Stake report, Schedule 13G/A, by FMR LLC10.2% of the class5%+ stakesSource
August 13, 2026Stake report, Schedule 13G, by Invesco Ltd.6.2% of the class5%+ stakesSource
August 6, 2026Stake report, Schedule 13G/A, by FMR LLC8.8% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G, by FMR LLC7% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by Invesco Ltd.4.9% of the class5%+ stakesSource
April 29, 2026Stake report, Schedule 13G, by Vanguard Capital Management7.38% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 12, 2026Stake report, Schedule 13G, by Invesco Ltd.5.5% of the class5%+ stakesSource
February 10, 2026Stake report, Schedule 13G/A, by Wellington Management Group LLP3.6% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by NOMURA HOLDINGS INC1.6% of the class5%+ stakesSource

Selling to them or working with them? See who runs Charles River Laboratories International, Inc. now and the warning signs.

Watch Charles River Laboratories International, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Charles River Laboratories International, Inc. and the records around it.

Charles River Laboratories International, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Charles River Laboratories International, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Charles River Laboratories International, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Charles River Laboratories International, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-18Reportednot named in the filing8-K, 2026-02-18
2026-01-09InChief Executive Officer2026-05-058-K, 2026-01-09

Who leads Charles River Laboratories International, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Charles River Laboratories International, Inc.?

New leaders reset buying decisions — get the Full Report on Charles River Laboratories International, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Charles River Laboratories International, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Executive Officer at Charles River Laboratories International, Inc., with the record behind each one.

Find candidates like Chief Executive Officer at Charles River Laboratories International, Inc.

Every change, in the filing's words

Filed 2026-02-18 · 8-K

Reported

On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer.

Also stated in this filing

  • Mr. Coleman will join the company with a tentative start date of April 6, 2026.
  • Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, including more than a decade of senior leadership roles in the healthcare sector.
  • Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1-billion healthcare services business.
  • Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation.
  • Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024.
  • Prior to DENTSPLY, he held operational and financial leadership positions at Integra Life Sciences from 2014 to 2022, including as Executive Vice President and Chief Operating Officer from 2019 to 2022, and previously as CFO and Corporate Vice President, International.
  • In addition to overseeing its Finance department as CFO, as Integra's COO, Mr. Coleman led operations and most of its talent force, including clinical, research and development, manufacturing, and quality functions while also leading the international team.
Filed 2026-01-09 · 8-K

Appointed: James C. Foster, Chief Executive Officer, effective 2026-05-05

Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairman of the Board, and Ms. Birgit Girshick, our Chief Operating Officer, will be appointed as our Chief Executive Officer, each effective as of May 5, 2026 (the "Transition Date").

Also stated in this filing

  • Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the "Board") of Charles River Laboratories International, Inc. (the "Company") announced a leadership transition plan.
  • Following the Transition Date, it is expected that Mr. Foster will remain a non-executive director of the Board.
  • Dr. Martin Mackay, current Lead Independent Director, is expected to become Chair of the Board, effective as of the Transition Date.
  • In addition, Ms. Girshick has been nominated by the Board to become a director of the Company effective at the 2026 Annual Meeting of Shareholders, which is expected to take place on the Transition Date.
  • Relatedly, the Board has approved increasing the size of the Board from 11 to 12, effective as of the Transition Date.
  • In connection with the increase in the size of the Board, each of Elliott Investment Management L.P, Elliott Associates, L.P., and Elliott International, L.P., provided a limited consent under the Cooperation Agreement with the Company, dated May 6, 2025, permitting the increase for Ms. Girshick to join the Board as contemplated.
  • Terms and Conditions of Ms. Girshick's Employment In connection with the announcement of Ms. Girshick's appointment as our Chief Executive Officer, the Company entered into a letter agreement with Ms. Girshick.

Tools for this story

Each opens in a new tab, filled in for Charles River Laboratories International, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/charles-river-laboratories-international
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Charles River Laboratories International, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/charles-river-laboratories-international